In summary, we have demonstrated that TKIs, those are approved for the treatment of HCC, can augment the IFNγ/STAT1 signaling pathway, and thereby increase the upregulation of cell surface HLA-I molecules in HCC cells. This evidence concerns the gene STAT1 and hepatocellular carcinoma.